$BIIB

As expected, FDA AdCom on $BIIB/Eisai lecanemab is setting up to be a "clearing the air" event after the whole Aduhelm saga. More importantly, FDA reviewer made it very clear the changes observed on the CDR-SB is considered "clinically meaningful". https://t.co/RLp7CwuFvs